Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 177 articles: HTML format

Single Articles

April 2024
1. MOYER CL, Lanier A, Qian J, Coleman D, et al
   IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy.
   Clin Cancer Res. 2024 Apr 5. doi: 10.1158/1078-0432.CCR-23-3839.
   PubMed     Abstract available
   
   
   
2. HAN YJ, Liu S, Hardeman A, Rajagopal PS, et al
   The VEGF-Hypoxia Signature is Upregulated in Basal like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer.
   Clin Cancer Res. 2024 Apr 2. doi: 10.1158/1078-0432.CCR-23-1526.
   PubMed     Abstract available
   
   
   
3. CONNOLLY RM, Wang V, Hyman DM, Grivas P, et al
   Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.
   Clin Cancer Res. 2024;30:1273-1280.
   PubMed     Abstract available
   
   
   March 2024
4. MAGBANUA MJM, Ahmed Z, Sayaman RW, Brown Swigart L, et al
   Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy.
   Clin Cancer Res. 2024 Mar 12. doi: 10.1158/1078-0432.CCR-23-2928.
   PubMed     Abstract available
   
   
   
5. MARTIN M, Yoder R, Salgado R, Del Monte-Millan M, et al
   Tumor-infiltrating lymphocytes refine outcomes in triple-negative breast cancer treated with anthracycline-free neoadjuvant chemotherapy.
   Clin Cancer Res. 2024 Mar 11. doi: 10.1158/1078-0432.CCR-24-0106.
   PubMed     Abstract available
   
   
   February 2024
6. GUARDUCCI C, Nardone A, Russo D, Nagy Z, et al
   Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor positive breast cancer.
   Clin Cancer Res. 2024 Feb 21. doi: 10.1158/1078-0432.CCR-23-2975.
   PubMed     Abstract available
   
   
   
7. MAMOUNAS EP, Bandos H, Rastogi P, Zhang Y, et al
   Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.
   Clin Cancer Res. 2024 Feb 20. doi: 10.1158/1078-0432.CCR-23-1977.
   PubMed     Abstract available
   
   
   
8. BARTLETT JMS, Xu K, Wong J, Pond G, et al
   Validation of the prognostic performance of Breast Cancer Index (BCI) in hormone receptor-positive (HR+) postmenopausal breast cancer patients in the TEAM trial.
   Clin Cancer Res. 2024 Feb 12. doi: 10.1158/1078-0432.CCR-23-2436.
   PubMed     Abstract available
   
   
   January 2024
9. TAN TJ, Sammons S, Im YH, She L, et al
   Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer.
   Clin Cancer Res. 2024 Jan 18. doi: 10.1158/1078-0432.CCR-23-2513.
   PubMed     Abstract available
   
   
   December 2023
10. MCTIERNAN A
    Diet Matters in Breast Cancer Prognosis: Clinical Trial Evidence and Questions.
    Clin Cancer Res. 2023 Dec 20. doi: 10.1158/1078-0432.CCR-23-3195.
    PubMed     Abstract available
    
    
    
11. ALBAIN KS, Yau C, Petricoin EF, Wolf DM, et al
    Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer in the adaptively randomized I-SPY2 trial - Efficacy and biomarker discovery.
    Clin Cancer Res. 2023 Dec 18. doi: 10.1158/1078-0432.CCR-22-2256.
    PubMed     Abstract available
    
    
    
12. CALVO V, Zheng W, Adam-Artigues A, Staschke KA, et al
    A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response-Dependent Survival of Quiescent Cancer Cells.
    Clin Cancer Res. 2023;29:5155-5172.
    PubMed     Abstract available
    
    
    
13. COAKLEY M, Villacampa G, Sritharan P, Swift C, et al
    Comparison of circulating tumor DNA assays for Molecular Residual Disease detection in early-stage triple negative breast cancer.
    Clin Cancer Res. 2023 Dec 11. doi: 10.1158/1078-0432.CCR-23-2326.
    PubMed     Abstract available
    
    
    
14. SCHMID P, Turner NC, Barrios CH, Isakoff SJ, et al
    First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results.
    Clin Cancer Res. 2023 Dec 7. doi: 10.1158/1078-0432.CCR-23-2084.
    PubMed     Abstract available
    
    
    
15. KIM H, Whitman AA, Wisniewska K, Kakati RT, et al
    Tamoxifen Response at Single-Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors.
    Clin Cancer Res. 2023;29:4894-4907.
    PubMed     Abstract available
    
    
    November 2023
16. CESCON DW, Hilton J, Morales Murilo S, Layman RM, et al
    A Phase I/II Study of GSK525762 Combined With Fulvestrant in Patients With Hormone Receptor-Positive/HER2-Negative (HR+/HER2-) Advanced or Metastatic Breast Cancer.
    Clin Cancer Res. 2023 Nov 22. doi: 10.1158/1078-0432.CCR-23-0133.
    PubMed     Abstract available
    
    
    
17. PRAT A, Solovieff N, Andre F, O'Shaughnessy J, et al
    Intrinsic subtype and overall survival of patients with advanced HR+/HER2- breast cancer treated with ribociclib and ET: correlative analysis of MONALEESA-2, -3, -7.
    Clin Cancer Res. 2023 Nov 8. doi: 10.1158/1078-0432.CCR-23-0561.
    PubMed     Abstract available
    
    
    
18. WILDIERS H, Armstrong A, Cuypere E, Dalenc F, et al
    Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase 2b Trial.
    Clin Cancer Res. 2023 Nov 8. doi: 10.1158/1078-0432.CCR-23-1173.
    PubMed     Abstract available
    
    
    
19. JHAVERI KL, Bellet-Ezquerra M, Turner NC, Loi S, et al
    Phase Ia/b Study of Giredestrant +/-Palbociclib and +/-Luteinizing Hormone-releasing Hormone Agonists in Estrogen Receptor-positive, HER2-negative, Locally Advanced/Metastatic Breast Cancer.
    Clin Cancer Res. 2023 Nov 3. doi: 10.1158/1078-0432.CCR-23-1796.
    PubMed     Abstract available
    
    
    
20. ROLFO C, Del Re M, Russo A
    Empower the Potential of Trastuzumab Deruxtecan with Novel Combinations.
    Clin Cancer Res. 2023;29:4317-4319.
    PubMed     Abstract available
    
    
    October 2023
21. TOLANEY SM, Goel S, Nadal J, Denys H, et al
    Overall survival and exploratory biomarker analyses of abemaciclib plus trastuzumab with or without fulvestrant vs trastuzumab plus chemotherapy in HR+, HER2+ metastatic breast cancer patients.
    Clin Cancer Res. 2023 Oct 31. doi: 10.1158/1078-0432.CCR-23-1209.
    PubMed     Abstract available
    
    
    
22. CONFORTI F, Pala L, De Pas T, Zattarin E, et al
    Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research.
    Clin Cancer Res. 2023 Oct 31. doi: 10.1158/1078-0432.CCR-23-1836.
    PubMed     Abstract available
    
    
    
23. GOETZ MP, Hamilton EP, Campone M, Hurvitz SA, et al
    Landscape of baseline and acquired genomic alterations in circulating tumor DNA with abemaciclib alone or with endocrine therapy in advanced breast cancer.
    Clin Cancer Res. 2023 Oct 27. doi: 10.1158/1078-0432.CCR-22-3573.
    PubMed     Abstract available
    
    
    
24. CONTE B, Boni L, Bisagni G, Durando A, et al
    SNPs of aromatase predict long-term survival and aromatase inhibitor toxicity in patients with early breast cancer: a biomarker analysis of the GIM4 and GIM5 trials.
    Clin Cancer Res. 2023 Oct 27. doi: 10.1158/1078-0432.CCR-23-1568.
    PubMed     Abstract available
    
    
    
25. WILKERSON AD, Parthasarathy PB, Stabellini N, Mitchell C, et al
    Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer.
    Clin Cancer Res. 2023 Oct 26. doi: 10.1158/1078-0432.CCR-23-1349.
    PubMed     Abstract available
    
    
    
26. BERRINO F, Villarini A, Gargano G, Krogh V, et al
    The effect of Diet on Breast Cancer recurrence: the DIANA-5 randomized trial.
    Clin Cancer Res. 2023 Oct 17. doi: 10.1158/1078-0432.CCR-23-1615.
    PubMed     Abstract available
    
    
    
27. HUANG H, Yao Y, Shen L, Jiang J, et al
    CD24hiCD27+Bregs within metastatic lymph nodes promote multi-drug resistance in breast cancer.
    Clin Cancer Res. 2023 Oct 13. doi: 10.1158/1078-0432.CCR-23-1759.
    PubMed     Abstract available
    
    
    
28. HUPPERT LA, Rugo HS
    Can We De-escalate Therapy for HER2-Positive Metastatic Breast Cancer?
    Clin Cancer Res. 2023 Oct 2. doi: 10.1158/1078-0432.CCR-23-1909.
    PubMed     Abstract available
    
    
    September 2023
29. RING A, Kilburn LS, Pearson A, Moretti L, et al
    Olaparib and celarasertib (AZD6738) in patients with triple negative advanced breast cancer: results from Cohort E of the plasmaMATCH trial (CRUK/15/010).
    Clin Cancer Res. 2023 Sep 29. doi: 10.1158/1078-0432.CCR-23-1696.
    PubMed     Abstract available
    
    
    
30. JOAQUIN GARCIA A, Rediti M, Venet D, Majjaj S, et al
    Differential benefit of metronomic chemotherapy among triple negative breast cancer subtypes treated in the IBCSG Trial 22-00.
    Clin Cancer Res. 2023 Sep 21. doi: 10.1158/1078-0432.CCR-23-1267.
    PubMed     Abstract available
    
    
    
31. CAO X, Muller KE, Chamberlin MD, Gui J, et al
    Near-infrared spectral tomography for predicting residual cancer burden during early stage neoadjuvant chemotherapy for breast cancer.
    Clin Cancer Res. 2023 Sep 21. doi: 10.1158/1078-0432.CCR-23-1593.
    PubMed     Abstract available
    
    
    
32. LINK T, Blohmer JU, Schmitt WD, Kuhlmann JD, et al
    RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial.
    Clin Cancer Res. 2023 Sep 19. doi: 10.1158/1078-0432.CCR-23-1801.
    PubMed     Abstract available
    
    
    
33. CROSBY EJ, Hartman ZC, Lyerly HK
    Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets.
    Clin Cancer Res. 2023;29:3256-3258.
    PubMed     Abstract available
    
    
    August 2023
34. GAO JJ, Osgood CL, Feng Z, Bloomquist EW, et al
    FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
    Clin Cancer Res. 2023 Aug 18:CCR-23-1133. doi: 10.1158/1078-0432.CCR-23-1133.
    PubMed     Abstract available
    
    
    
35. TEW BY, Kalfa AJ, Yang Z, Hurth KM, et al
    ATM-inhibitor AZD1390 is a radiosensitizer for breast cancer CNS metastasis.
    Clin Cancer Res. 2023 Aug 16:CCR-23-0290. doi: 10.1158/1078-0432.CCR-23-0290.
    PubMed     Abstract available
    
    
    
36. TOVEY H, Sipos O, Parker JS, Hoadley KA, et al
    Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727).
    Clin Cancer Res. 2023 Aug 14:OF1-OF15. doi: 10.1158/1078-0432.CCR-23-0370.
    PubMed     Abstract available
    
    
    
37. DEGNIM AC, Siontis BL, Ahmed SK, Hoskin TL, et al
    Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast.
    Clin Cancer Res. 2023;29:2885-2893.
    PubMed     Abstract available
    
    
    July 2023
38. PASCUAL J, Gil-Gil M, Proszek P, Zielinski C, et al
    Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients.
    Clin Cancer Res. 2023 Jul 25:CCR-23-0956. doi: 10.1158/1078-0432.CCR-23-0956.
    PubMed     Abstract available
    
    
    
39. MEDFORD AJ, Moy B, Spring LM, Hurvitz SA, et al
    Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception.
    Clin Cancer Res. 2023 Jul 21:CCR-23-0757. doi: 10.1158/1078-0432.CCR-23-0757.
    PubMed     Abstract available
    
    
    
40. LEFRERE H, Moore K, Floris G, Sanders J, et al
    Poor outcome in postpartum breast cancer patients is associated with distinct molecular and immunological features.
    Clin Cancer Res. 2023 Jul 14:CCR-22-3645. doi: 10.1158/1078-0432.CCR-22-3645.
    PubMed     Abstract available
    
    
    
41. TRAPHAGEN NA, Schwartz GN, Tau S, Roberts AM, et al
    Estrogen therapy induces receptor-dependent DNA damage enhanced by PARP inhibition in ER+ breast cancer.
    Clin Cancer Res. 2023 Jul 13:CCR-23-0488. doi: 10.1158/1078-0432.CCR-23-0488.
    PubMed     Abstract available
    
    
    
42. STOLAROVA L, Kleiblova P, Zemankova P, Stastna B, et al
    ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk.
    Clin Cancer Res. 2023 Jul 13:OF1-OF14. doi: 10.1158/1078-0432.CCR-23-0212.
    PubMed     Abstract available
    
    
    
43. WILLIAMS TM, Schneeweiss A, Jackisch C, Shen C, et al
    Caveolin gene expression predicts clinical outcomes for early-stage HER2-negative breast cancer treated with paclitaxel-based chemotherapy in the GeparSepto trial.
    Clin Cancer Res. 2023 Jul 11:CCR-23-0362. doi: 10.1158/1078-0432.CCR-23-0362.
    PubMed     Abstract available
    
    
    
44. MIGLIETTA F, Ragazzi M, Fernandes B, Griguolo G, et al
    A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer.
    Clin Cancer Res. 2023 Jul 7:CCR-23-0480. doi: 10.1158/1078-0432.CCR-23-0480.
    PubMed     Abstract available
    
    
    
45. RAGHAV KPS, Moasser MM
    Molecular Pathways and Mechanisms of HER2 in Cancer Therapy.
    Clin Cancer Res. 2023;29:2351-2361.
    PubMed     Abstract available
    
    
    
46. MARON SB, Chatila W, Walch H, Chou JF, et al
    Determinants of survival in HER2+ metastatic esophagogastric cancer.
    Clin Cancer Res. 2023 Jul 5:CCR-22-3769. doi: 10.1158/1078-0432.CCR-22-3769.
    PubMed     Abstract available
    
    
    June 2023
47. SHAGISULTANOVA E, Gradishar W, Brown-Glabberman U, Chalasani P, et al
    Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer.
    Clin Cancer Res. 2023 Jun 26:CCR-23-0117. doi: 10.1158/1078-0432.CCR-23-0117.
    PubMed     Abstract available
    
    
    
48. CASAK SJ, Horiba MN, Yuan M, Cheng J, et al
    FDA Approval Summary: Tucatinib with trastuzumab for advanced unresectable or metastatic, chemotherapy refractory, HER2 positive RAS wild type colorectal cancer.
    Clin Cancer Res. 2023 Jun 15:CCR-23-1041. doi: 10.1158/1078-0432.CCR-23-1041.
    PubMed     Abstract available
    
    
    
49. KABRAJI S, Lin NU
    Keeping it in the family: HER3 as a target in brain metastases.
    Clin Cancer Res. 2023 Jun 12:CCR-23-1107. doi: 10.1158/1078-0432.CCR-23-1107.
    PubMed     Abstract available
    
    
    
50. RAO X, Chen Y, Beyrer J, Nash Smyth E, et al
    Clinical and Genomic Characteristics of Patients with HR+, HER2- Metastatic Breast Cancer Following Progression on a CDK4 and 6 Inhibitor.
    Clin Cancer Res. 2023 Jun 8:CCR-22-3843. doi: 10.1158/1078-0432.CCR-22-3843.
    PubMed     Abstract available
    
    
    
51. HENSING WL, Gerratana L, Clifton K, Medford AJ, et al
    Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer.
    Clin Cancer Res. 2023 Jun 2:CCR-22-3785. doi: 10.1158/1078-0432.CCR-22-3785.
    PubMed     Abstract available
    
    
    
52. CHANDARLAPATY S, Dickler MN, Perez Fidalgo JA, Villanueva-Vazquez R, et al
    An open-label phase I study of GDC-0927 in postmenopausal women with locally advanced or metastatic estrogen receptor positive breast cancer.
    Clin Cancer Res. 2023 Jun 1:CCR-23-0011. doi: 10.1158/1078-0432.CCR-23-0011.
    PubMed     Abstract available
    
    
    
53. SCHWARTZ GN, Kaufman PA, Giridhar KV, Marotti JD, et al
    Alternating 17beta-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer.
    Clin Cancer Res. 2023 Jun 1:OF1-OF7. doi: 10.1158/1078-0432.CCR-23-0112.
    PubMed     Abstract available
    
    
    May 2023
54. VEERARAGHAVAN J, Gutierrez C, De Angelis C, Davis R, et al
    A multiparameter molecular classifier to predict response to neoadjuvant lapatinib plus trastuzumab without chemotherapy in HER2+ breast cancer.
    Clin Cancer Res. 2023 May 17:CCR-22-3753. doi: 10.1158/1078-0432.CCR-22-3753.
    PubMed     Abstract available
    
    
    
55. SCHWARTZ GN, Kaufman PA, Giridhar KV, Marotti JD, et al
    Alternating 17beta-estradiol and aromatase inhibitor therapies is efficacious in post-menopausal women with advanced endocrine-resistant ER+ breast cancer.
    Clin Cancer Res. 2023 May 15:CCR-23-0112. doi: 10.1158/1078-0432.CCR-23-0112.
    PubMed     Abstract available
    
    
    
56. STENMARK TULLBERG A, Sjostrom M, Nimeus E, Killander F, et al
    Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial.
    Clin Cancer Res. 2023;29:1783-1793.
    PubMed     Abstract available
    
    
    
57. RASSY E, Garberis I, Tran-Dien A, Job B, et al
    Comparative Genomic Profiling of Second Breast Cancers following First Ipsilateral Hormone Receptor-Positive Breast Cancers.
    Clin Cancer Res. 2023;29:1822-1831.
    PubMed     Abstract available
    
    
    April 2023
58. GIBSON CJ, Fell GG, Sella T, Sperling AS, et al
    Clonal Hematopoiesis in Young Women Treated for Breast Cancer.
    Clin Cancer Res. 2023 Apr 28:CCR-23-0050. doi: 10.1158/1078-0432.CCR-23-0050.
    PubMed     Abstract available
    
    
    
59. DISIS ML, Dang Y, Coveler AL, Childs JS, et al
    A Phase I/II trial of HER-2/neu vaccine primed autologous T-cell infusions in patients with treatment refractory HER-2/neu overexpressing breast cancer.
    Clin Cancer Res. 2023 Apr 24:CCR-22-3578. doi: 10.1158/1078-0432.CCR-22-3578.
    PubMed     Abstract available
    
    
    
60. CLARK AS, Hong F, Finn RS, DeMichele AM, et al
    Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B.
    Clin Cancer Res. 2023;29:1477-1483.
    PubMed     Abstract available
    
    
    
61. TOMASICH E, Steindl A, Paiato C, Hatziioannou T, et al
    Frequent overexpression of HER3 in brain metastases from breast and lung cancer.
    Clin Cancer Res. 2023 Apr 10:CCR-23-0020. doi: 10.1158/1078-0432.CCR-23-0020.
    PubMed     Abstract available
    
    
    
62. FASCHING PA, Szeto C, Denkert C, Benz S, et al
    Inferred immune-cell activity is an independent predictor of HER2 negative breast cancer prognosis and response to paclitaxel-based therapy in the GeparSepto trial.
    Clin Cancer Res. 2023 Apr 4:CCR-22-2213. doi: 10.1158/1078-0432.CCR-22-2213.
    PubMed     Abstract available
    
    
    March 2023
63. LINDEN HM, Mankoff DA
    Can Molecular Imaging Find a Path to Navigate Evolving Breast Cancer Treatments?
    Clin Cancer Res. 2023 Mar 29:CCR-23-0393. doi: 10.1158/1078-0432.CCR-23-0393.
    PubMed     Abstract available
    
    
    
64. TAU S, Miller TW
    Alpelisib Efficacy without Cherry-PI3King Mutations.
    Clin Cancer Res. 2023;29:989-990.
    PubMed     Abstract available
    
    
    
65. SIVAKUMAR S, Jin DX, Rathod R, Ross J, et al
    Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations.
    Clin Cancer Res. 2023;29:1125-1136.
    PubMed     Abstract available
    
    
    
66. RUGO HS, Raskina K, Schrock AB, Madison RW, et al
    Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma.
    Clin Cancer Res. 2023;29:1056-1067.
    PubMed     Abstract available
    
    
    February 2023
67. GRAESER M, Gluz O, Biehl C, Ulbrich-Gebauer D, et al
    Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial.
    Clin Cancer Res. 2023;29:805-814.
    PubMed     Abstract available
    
    
    
68. GUERRERO-ZOTANO A, Belli S, Zielinski C, Gil-Gil M, et al
    CCNE1 and PLK1 mediates resistance to palbociclib in HR+/HER2- metastatic breast cancer.
    Clin Cancer Res. 2023 Feb 7:CCR-22-2206. doi: 10.1158/1078-0432.CCR-22-2206.
    PubMed     Abstract available
    
    
    
69. IQBAL R, Yaqub M, Bektas HO, Oprea-Lager DE, et al
    [18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant.
    Clin Cancer Res. 2023 Feb 3:CCR-22-2720. doi: 10.1158/1078-0432.CCR-22-2720.
    PubMed     Abstract available
    
    
    
70. DENKERT C, Lambertini C, Fasching PA, Pogue-Geile KL, et al
    Biomarker Data From the Phase III KATHERINE Study of Adjuvant T-DM1 Versus Trastuzumab for Residual Invasive Disease After Neoadjuvant Therapy for HER2-Positive Breast Cancer.
    Clin Cancer Res. 2023 Feb 2:CCR-22-1989. doi: 10.1158/1078-0432.CCR-22-1989.
    PubMed     Abstract available
    
    
    January 2023
71. ARPINO G, de la Haba-Rodriguez J, Ferrero JM, De Placido S, et al
    Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic/Locally Advanced Breast Cancer: PERTAIN Final Analysis.
    Clin Cancer Res. 2023 Jan 30:CCR-22-1092. doi: 10.1158/1078-0432.CCR-22-1092.
    PubMed     Abstract available
    
    
    
72. JENKINS S, Zhang W, Steinberg SM, Nousome D, et al
    Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases.
    Clin Cancer Res. 2023 Jan 27:CCR-22-0855. doi: 10.1158/1078-0432.CCR-22-0855.
    PubMed     Abstract available
    
    
    
73. DAVIS AA, Luo J, Zheng T, Dai C, et al
    Genomic complexity predicts resistance to endocrine therapy and CDK4/6 inhibition in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer.
    Clin Cancer Res. 2023 Jan 24:CCR-22-2177. doi: 10.1158/1078-0432.CCR-22-2177.
    PubMed     Abstract available
    
    
    
74. NEDERLOF I, Voorwerk L, Kok M
    Facts and hopes in immunotherapy for early-stage triple-negative breast cancer.
    Clin Cancer Res. 2023 Jan 9:CCR-22-0701. doi: 10.1158/1078-0432.CCR-22-0701.
    PubMed     Abstract available
    
    
    December 2022
75. RONCHI C, Brisken C
    Targeting the progesterone receptor in breast cancer: mind the short form!
    Clin Cancer Res. 2022 Dec 22:CCR-22-3374. doi: 10.1158/1078-0432.CCR-22-3374.
    PubMed     Abstract available
    
    
    
76. VISVANATHAN K, Cope L, Fackler MJ, Considine M, et al
    Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial.
    Clin Cancer Res. 2022 Dec 19:CCR-22-2128. doi: 10.1158/1078-0432.CCR-22-2128.
    PubMed     Abstract available
    
    
    
77. ROBERTSON JFR, Coleman RE, Cheung KL, Evans A, et al
    Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).
    Clin Cancer Res. 2022;28:5469.
    PubMed    
    
    
    
78. ROELOFS PA, Martens JWM, Harris RS, Span PN, et al
    Clinical Implications of APOBEC3-mediated Mutagenesis in Breast Cancer.
    Clin Cancer Res. 2022 Dec 8:CCR-22-2861. doi: 10.1158/1078-0432.CCR-22-2861.
    PubMed     Abstract available
    
    
    November 2022
79. MATIKAS A, Johansson H, Gryback P, Bjohle J, et al
    Survival outcomes, digital TILs and on-treatment PET/CT during neoadjuvant therapy for HER2-positive breast cancer: results from the randomized PREDIX HER2 trial.
    Clin Cancer Res. 2022 Nov 30:CCR-22-2829. doi: 10.1158/1078-0432.CCR-22-2829.
    PubMed     Abstract available
    
    
    
80. PIETRANTONIO F, Manca P, Bellomo SE, Corso S, et al
    HER2 copy number and resistance mechanisms in patients with HER2-positive advanced gastric cancer receiving initial trastuzumab-based therapy in JACOB trial.
    Clin Cancer Res. 2022 Nov 22:CCR-22-2533. doi: 10.1158/1078-0432.CCR-22-2533.
    PubMed     Abstract available
    
    
    
81. ASLEH K, Lluch A, Goytain A, Barrios C, et al
    Triple negative PAM50 non-basal breast cancer subtype predicts benefit from extended adjuvant capecitabine.
    Clin Cancer Res. 2022 Nov 8. pii: 710523. doi: 10.1158/1078-0432.CCR-22-2191.
    PubMed     Abstract available
    
    
    October 2022
82. SOFFIETTI R, Pellerino A
    Brain metastasis from HER2-positive breast cancer: an evolving landscape.
    Clin Cancer Res. 2022 Oct 28. pii: 710102. doi: 10.1158/1078-0432.CCR-22-2853.
    PubMed     Abstract available
    
    
    
83. ELIA A, Saldain L, Vanzulli SI, Helguero LA, et al
    Beneficial effects of mifepristone treatment in breast cancer patients selected by the progesterone receptor isoform ratio: Results from the MIPRA trial.
    Clin Cancer Res. 2022 Oct 21. pii: 709943. doi: 10.1158/1078-0432.CCR-22-2060.
    PubMed     Abstract available
    
    
    
84. GAZINSKA P, Milton C, Iacovacci J, Ward J, et al
    Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers.
    Clin Cancer Res. 2022;28:4494-4508.
    PubMed     Abstract available
    
    
    
85. TSUJI J, Li T, Grinshpun A, Coorens T, et al
    Clinical Efficacy and Whole Exome Sequencing of Liquid Biopsies in a Phase IB/II study of Bazedoxifene and Palbociclib in Hormone Receptor-Positive Breast Cancer.
    Clin Cancer Res. 2022 Oct 10. pii: 709684. doi: 10.1158/1078-0432.CCR-22-2305.
    PubMed     Abstract available
    
    
    September 2022
86. ALBANELL J, Perez-Garcia JM, Gil-Gil M, Curigliano G, et al
    Palbociclib Rechallenge for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial.
    Clin Cancer Res. 2022 Sep 27. pii: 709486. doi: 10.1158/1078-0432.CCR-22-1281.
    PubMed     Abstract available
    
    
    
87. PLYM A, Zhang Y, Stopsack KH, Jee YH, et al
    Family history of prostate and breast cancer integrated with a polygenic risk score identifies men at highest risk of dying from prostate cancer before age 75 years.
    Clin Cancer Res. 2022 Sep 14. pii: 709205. doi: 10.1158/1078-0432.CCR-22-1723.
    PubMed     Abstract available
    
    
    
88. SHARMA P
    Time to optimize de-escalation strategies in triple-negative breast cancer?
    Clin Cancer Res. 2022 Sep 9. pii: 709144. doi: 10.1158/1078-0432.CCR-22-2140.
    PubMed     Abstract available
    
    
    
89. KABRAJI S, Ni J, Sammons S, Li T, et al
    Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases.
    Clin Cancer Res. 2022 Sep 8. pii: 709125. doi: 10.1158/1078-0432.CCR-22-1138.
    PubMed     Abstract available
    
    
    
90. FOLDI J, Kahn A, Silber A, Qing T, et al
    Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.
    Clin Cancer Res. 2022;28:3720-3728.
    PubMed     Abstract available
    
    
    
91. HU C, Susswein LR, Roberts ME, Yang H, et al
    Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay.
    Clin Cancer Res. 2022;28:3742-3751.
    PubMed     Abstract available
    
    
    
92. BATALINI F, Gulhan DC, Mao V, Tran A, et al
    Mutational signature 3 detected from clinical panel sequencing is associated with responses to olaparib in breast and ovarian cancers.
    Clin Cancer Res. 2022 Sep 1. pii: 708955. doi: 10.1158/1078-0432.CCR-22-0749.
    PubMed     Abstract available
    
    
    August 2022
93. CONSTANTINIDOU A, Marcou Y, Toss MS, Simmons T, et al
    Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-positive, HER2-negative Primary Breast Cancer.
    Clin Cancer Res. 2022 Aug 31. pii: 708058. doi: 10.1158/1078-0432.CCR-22-0619.
    PubMed     Abstract available
    
    
    
94. CRISTOFANILLI M, Rugo HS, Im SA, Slamon DJ, et al
    Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.
    Clin Cancer Res. 2022;28:3433-3442.
    PubMed     Abstract available
    
    
    
95. SHAH M, Osgood CL, Amatya AK, Fiero MH, et al
    FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple Negative Breast Cancer.
    Clin Cancer Res. 2022 Aug 4. pii: 707438. doi: 10.1158/1078-0432.CCR-22-1110.
    PubMed     Abstract available
    
    
    
96. SINGER CF, Holst F, Steurer S, Burandt EC, et al
    Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer.
    Clin Cancer Res. 2022 Aug 3:OF1-OF9. doi: 10.1158/1078-0432.CCR-21-4328.
    PubMed     Abstract available
    
    
    July 2022
97. SUN K, Xu Y, Zhang L, Niravath P, et al
    A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple Negative Breast Cancer.
    Clin Cancer Res. 2022 Jul 25. pii: 707209. doi: 10.1158/1078-0432.CCR-22-0622.
    PubMed     Abstract available
    
    
    
98. GLUZ O, Nitz U, Kolberg-Liedtke C, Prat A, et al
    De-escalated neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Impact of molecular markers and survival analysis of the WSG-ADAPT-TN trial.
    Clin Cancer Res. 2022 Jul 7. pii: 706903. doi: 10.1158/1078-0432.CCR-22-0482.
    PubMed     Abstract available
    
    
    
99. SALGADO R, Loi S
    What's in a Name? That Which We Call Immune Cells by Any Other Name Would All Smell as Sweet.
    Clin Cancer Res. 2022;28:2728-2729.
    PubMed     Abstract available
    
    
    June 2022
100. ZHANG J, Ji D, Shen W, Xiao Q, et al
     Phase I Trial of a Novel Anti-HER2 Antibody-Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer.
     Clin Cancer Res. 2022 Jun 29:OF1-OF10. doi: 10.1158/1078-0432.CCR-22-0456.
     PubMed     Abstract available
     
     
     
101. KUMAR T, Hobbs E, Yang F, Chang JT, et al
     Tumor immune microenvironment changes by multiplex immunofluorescence staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a hereditary BRCA mutation.
     Clin Cancer Res. 2022 Jun 23. pii: 705099. doi: 10.1158/1078-0432.CCR-21-1278.
     PubMed     Abstract available
     
     
     
102. LI J, Jiang J, Bao X, Kumar V, et al
     Mechanistic Modeling of Central Nervous System Pharmacokinetics and Target Engagement of HER2 Tyrosine Kinase Inhibitors to Inform Treatment of Breast Cancer Brain Metastases.
     Clin Cancer Res. 2022 Jun 21:OF1-OF13. doi: 10.1158/1078-0432.CCR-22-0405.
     PubMed     Abstract available
     
     
     
103. YIN W, Wang Y, Wu Z, Ye Y, et al
     Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study.
     Clin Cancer Res. 2022 Jun 17. pii: 704938. doi: 10.1158/1078-0432.CCR-22-0446.
     PubMed     Abstract available
     
     
     
104. XIA Y, He X, Renshaw L, Martinez-Perez C, et al
     Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer.
     Clin Cancer Res. 2022 Jun 2. pii: 699314. doi: 10.1158/1078-0432.CCR-21-3189.
     PubMed     Abstract available
     
     
     
105. FASCHING PA, Liu D, Scully S, Ingle JN, et al
     Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Breast Cancer Patients.
     Clin Cancer Res. 2022 Jun 2. pii: 699313. doi: 10.1158/1078-0432.CCR-20-4774.
     PubMed     Abstract available
     
     
     
106. SUMAN VJ, Du L, Hoskin T, Anurag M, et al
     Evaluation of sensitivity to endocrine therapy index (SET2,3) for response to neoadjuvant endocrine therapy and longer-term breast cancer patient outcomes (Alliance Z1031).
     Clin Cancer Res. 2022 Jun 2. pii: 699315. doi: 10.1158/1078-0432.CCR-22-0068.
     PubMed     Abstract available
     
     
     
107. BYCHKOVSKY BL, Li T, Sotelo J, Tayob N, et al
     Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program.
     Clin Cancer Res. 2022;28:2349-2360.
     PubMed     Abstract available
     
     
     May 2022
108. ZHANG J, Ji D, Shen W, Xiao Q, et al
     Phase I Trial of a Novel Anti-HER2 Antibody-drug Conjugate, ARX788, for the Treatment of HER2-positive Metastatic Breast Cancer.
     Clin Cancer Res. 2022 May 26. pii: 699249. doi: 10.1158/1078-0432.CCR-22-0456.
     PubMed     Abstract available
     
     
     
109. LINDEMAN GJ, Fernando TM, Bowen R, Jerzak KJ, et al
     VERONICA: Randomized Phase 2 Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, Biomarker Results.
     Clin Cancer Res. 2022 May 18. pii: 699022. doi: 10.1158/1078-0432.CCR-21-3811.
     PubMed     Abstract available
     
     
     
110. BONI V, Fidler MJ, Arkenau HT, Spira A, et al
     Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.
     Clin Cancer Res. 2022;28:2020-2029.
     PubMed     Abstract available
     
     
     
111. DMELLO C, Sonabend A, Arrieta VA, Zhang DY, et al
     Translocon-associated protein subunit SSR3 determines and predicts susceptibility to paclitaxel in breast cancer and glioblastoma.
     Clin Cancer Res. 2022 May 12. pii: 698878. doi: 10.1158/1078-0432.CCR-21-2563.
     PubMed     Abstract available
     
     
     
112. RADOVICH M, Solzak JP, Wang CJ, Hancock BA, et al
     Initial phase I safety study of gedatolisib plus cofetuzumab pelidotin for patients with metastatic triple-negative breast cancer.
     Clin Cancer Res. 2022 May 12. pii: 698879. doi: 10.1158/1078-0432.CCR-21-3078.
     PubMed     Abstract available
     
     
     
113. COLEMAN IM, DeSarkar N, Morrissey C, Xin L, et al
     Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration Resistant Prostate Cancer.
     Clin Cancer Res. 2022 May 12. pii: 698880. doi: 10.1158/1078-0432.CCR-21-4289.
     PubMed     Abstract available
     
     
     
114. YAM C, Abuhadra N, Sun R, Adrada BE, et al
     Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer.
     Clin Cancer Res. 2022 May 4. pii: 696297. doi: 10.1158/1078-0432.CCR-21-3100.
     PubMed     Abstract available
     
     
     April 2022
115. TOLANEY SM, Toi M, Neven P, Sohn J, et al
     Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.
     Clin Cancer Res. 2022;28:1500-1506.
     PubMed     Abstract available
     
     
     
116. BLENMAN KRM, Marczyk M, Karn T, Qing T, et al
     Predictive markers of response to neoadjuvant durvalumab with nab-paclitaxel and dose dense doxorubicin/cyclophosphamide in basal-like triple negative breast cancer.
     Clin Cancer Res. 2022 Apr 4. pii: 694190. doi: 10.1158/1078-0432.CCR-21-3215.
     PubMed     Abstract available
     
     
     
117. LIM JSJ, Wong ALA, Ow SGW, Ngoi NYL, et al
     Phase Ib/II dose expansion study of lenvatinib combined with letrozole in post-menopausal women with hormone receptor positive breast cancer.
     Clin Cancer Res. 2022 Apr 1. pii: 694118. doi: 10.1158/1078-0432.CCR-21-4179.
     PubMed     Abstract available
     
     
     
118. WESTPHALEN CB, Fine AD, Andre F, Ganesan S, et al
     Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score.
     Clin Cancer Res. 2022;28:1412-1421.
     PubMed     Abstract available
     
     
     March 2022
119. YEHIA L, Eng C
     One Size Does Not Fit All: Breast Cancer in Young Women.
     Clin Cancer Res. 2022 Mar 23. pii: 688107. doi: 10.1158/1078-0432.CCR-22-0352.
     PubMed     Abstract available
     
     
     
120. BERGAMINO MA, Morani G, Parker J, Schuster EF, et al
     Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor-positive Breast Cancers.
     Clin Cancer Res. 2022;28:1217-1228.
     PubMed     Abstract available
     
     
     
121. VIGANO L, Locatelli A, Ulisse A, Galbardi B, et al
     Modulation of the estrogen/erbB2 receptors crosstalk by CDK4/6 inhibition triggers sustained senescence in estrogen receptor and erbB2 positive breast cancer.
     Clin Cancer Res. 2022 Mar 7. pii: 682079. doi: 10.1158/1078-0432.CCR-21-3185.
     PubMed     Abstract available
     
     
     
122. CHEN L, Jiang YZ, Wu SY, Wu J, et al
     Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-PLUS): an open-label, single-arm, phase 2 trial.
     Clin Cancer Res. 2022 Mar 3. pii: 681997. doi: 10.1158/1078-0432.CCR-21-4313.
     PubMed     Abstract available
     
     
     February 2022
123. LENOUE-NEWTON ML, Chen SC, Stricker T, Hyman DM, et al
     Natural history and characteristics of ERBB2-mutated hormone receptor-positive advanced breast cancer: a retrospective case-control study from AACR Project GENIE.
     Clin Cancer Res. 2022 Feb 18. pii: 681702. doi: 10.1158/1078-0432.CCR-21-0885.
     PubMed     Abstract available
     
     
     
124. BUNDRED N, Porta N, Brunt AM, Cramer A, et al
     Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.
     Clin Cancer Res. 2022 Feb 14. pii: 1078-0432.CCR-21-3177.
     PubMed     Abstract available
     
     
     
125. BATALINI F, Xiong N, Tayob N, Polak M, et al
     Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer.
     Clin Cancer Res. 2022 Feb 11. pii: 1078-0432.CCR-21-3045.
     PubMed     Abstract available
     
     
     
126. BARTLETT JMS, Sgroi DC, Treuner K, Zhang Y, et al
     Breast Cancer Index is a predictive biomarker of treatment benefit and outcome from extended tamoxifen therapy: final analysis of the Trans-aTTom study.
     Clin Cancer Res. 2022 Feb 10. pii: 1078-0432.CCR-21-3385.
     PubMed     Abstract available
     
     
     
127. KURANI H, Razavipour SF, Harikumar KB, Dunworth M, et al
     DOT1L is a novel cancer stem cell target for triple negative breast cancer.
     Clin Cancer Res. 2022 Feb 8. pii: 1078-0432.CCR-21-1299.
     PubMed     Abstract available
     
     
     
128. PEDDI PF, Fasching PA, Liu D, Quinaux E, et al
     Genetic polymorphisms and correlation with treatment induced cardiotoxicity and prognosis in breast cancer patients.
     Clin Cancer Res. 2022 Feb 2. pii: 1078-0432.CCR-21-1762.
     PubMed     Abstract available
     
     
     January 2022
129. WAKS AG, Kim D, Jain E, Snow C, et al
     Somatic and germline genomic alterations in very young women with breast cancer.
     Clin Cancer Res. 2022 Jan 31. pii: 1078-0432.CCR-21-2572.
     PubMed     Abstract available
     
     
     
130. BLUM JL, Laird AD, Litton JK, Rugo HS, et al
     Determinants of Response to Talazoparib in Patients with HER2-negative, Germline BRCA1/2-mutated Breast Cancer.
     Clin Cancer Res. 2022 Jan 28. pii: 1078-0432.CCR-21-2080.
     PubMed     Abstract available
     
     
     
131. MA CX, Luo J, Freedman RA, Pluard TJ, et al
     The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2 mutated, non-amplified metastatic breast cancer.
     Clin Cancer Res. 2022 Jan 19. pii: 1078-0432.CCR-21-3418.
     PubMed     Abstract available
     
     
     
132. SCHWARTZ CJ, da Silva EM, Marra A, Gazzo AM, et al
     Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome.
     Clin Cancer Res. 2022;28:404-413.
     PubMed     Abstract available
     
     
     
133. GARCIA-SAENZ JA, Martinez-Janez N, Cubedo R, Jerez Y, et al
     Sapanisertib Plus Fulvestrant in Post-Menopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer After Progression on Aromatase Inhibitor.
     Clin Cancer Res. 2022 Jan 3. pii: 1078-0432.CCR-21-2652.
     PubMed     Abstract available
     
     
     December 2021
134. KESTER L, Seinstra D, van Rossum AGJ, Vennin C, et al
     Differential survival and therapy benefit of breast cancer patients are characterized by distinct epithelial and immune cell microenvironments.
     Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-1442.
     PubMed     Abstract available
     
     
     
135. LU YS, Im SA, Colleoni M, Franke F, et al
     Updated Overall Survival of Ribociclib Plus Endocrine Therapy vs Endocrine Therapy Alone in Pre- and Perimenopausal Patients With HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.
     Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-3032.
     PubMed     Abstract available
     
     
     
136. FITZPATRICK A, Iravani M, Mills A, Childs L, et al
     Assessing CSF ctDNA to improve diagnostic accuracy and therapeutic monitoring in breast cancer leptomeningeal metastasis.
     Clin Cancer Res. 2021 Dec 17. pii: 1078-0432.CCR-21-3017.
     PubMed     Abstract available
     
     
     
137. ROYCE M, Osgood CL, Amatya AK, Fiero MH, et al
     FDA Approval Summary: Margetuximab plus chemotherapy for advanced or metastatic HER2-positive breast cancer.
     Clin Cancer Res. 2021 Dec 16. pii: 1078-0432.CCR-21-3247.
     PubMed     Abstract available
     
     
     
138. DI NOIA V, Pimpinelli F, Renna D, Barberi V, et al
     Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution.
     Clin Cancer Res. 2021;27:6815-6823.
     PubMed     Abstract available
     
     
     
139. SHI Z, Wulfkuhle J, Nowicka M, Gallagher RI, et al
     Functional Mapping of AKT Signaling and Biomarkers of Response From the FAIRLANE Trial of Neoadjuvant Ipatasertib Plus Paclitaxel for Triple-Negative Breast Cancer.
     Clin Cancer Res. 2021 Dec 14. pii: 1078-0432.CCR-21-2498.
     PubMed     Abstract available
     
     
     
140. TAN AR, Wright GS, Thummala AR, Danso MA, et al
     Trilaciclib prior to chemotherapy in patients with metastatic triple-negative breast cancer: final efficacy and subgroup analysis from a randomized phase II study.
     Clin Cancer Res. 2021 Dec 9. pii: 1078-0432.CCR-21-2272.
     PubMed     Abstract available
     
     
     
141. ZHOU Q, Gampenrieder SP, Frantal S, Rinnerthaler G, et al
     Persistence of ctDNA in breast cancer patients during neoadjuvant treatment is a significant predictor of poor tumour response.
     Clin Cancer Res. 2021 Dec 3. pii: 1078-0432.CCR-21-3231.
     PubMed     Abstract available
     
     
     
142. ATRAFI F, Boix O, Subbiah V, Diamond JR, et al
     A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.
     Clin Cancer Res. 2021;27:6366-6375.
     PubMed     Abstract available
     
     
     November 2021
143. MOORE HCF, Barlow WE, Somlo G, Gralow JR, et al
     A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222.
     Clin Cancer Res. 2021 Nov 29. pii: 1078-0432.CCR-21-3131.
     PubMed     Abstract available
     
     
     
144. ZHANG J, Ji D, Cai L, Yao H, et al
     First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study.
     Clin Cancer Res. 2021 Nov 29. pii: 1078-0432.CCR-21-2827.
     PubMed     Abstract available
     
     
     
145. HUA X, Bi XW, Zhao JL, Shi YX, et al
     Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Metastatic Breast Cancer with Hormone Receptor-positive and HER2-positive (SYSUCC-002).
     Clin Cancer Res. 2021 Nov 22. pii: 1078-0432.CCR-21-3435.
     PubMed     Abstract available
     
     
     
146. NIE P, Kalidindi T, Nagle VL, Wu X, et al
     Imaging of Cancer gamma-Secretase Activity Using an Inhibitor-Based PET Probe.
     Clin Cancer Res. 2021;27:6145-6155.
     PubMed     Abstract available
     
     
     
147. LLOYD MR, Spring LM, Bardia A, Wander SA, et al
     Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer and Emerging Therapeutic Opportunities.
     Clin Cancer Res. 2021 Nov 1. pii: 1078-0432.CCR-21-2947.
     PubMed     Abstract available
     
     
     
148. SARDESAI SD, Thomas A, Gallagher C, Lynce F, et al
     Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC.
     Clin Cancer Res. 2021;27:5810-5817.
     PubMed     Abstract available
     
     
     October 2021
149. ADAMS S, Othus M, Patel SP, Miller KD, et al
     A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).
     Clin Cancer Res. 2021 Oct 29. pii: 1078-0432.CCR-21-2182.
     PubMed     Abstract available
     
     
     
150. ARORA S, Narayan P, Osgood CL, Wedam S, et al
     U.S. FDA Drug Approvals for Breast Cancer - A Decade in Review.
     Clin Cancer Res. 2021 Oct 28. pii: 1078-0432.CCR-21-2600.
     PubMed     Abstract available
     
     
     
151. DIECI MV, Guarneri V, Tosi A, Bisagni G, et al
     Neoadjuvant chemotherapy and immunotherapy in Luminal B-like breast cancer: results of the phase II GIADA trial.
     Clin Cancer Res. 2021 Oct 19. pii: 1078-0432.CCR-21-2260.
     PubMed     Abstract available
     
     
     
152. SYMMANS WF
     Interpreting the Complex Landscape of Immune-Tumor Interface.
     Clin Cancer Res. 2021;27:5446-5448.
     PubMed     Abstract available
     
     
     
153. VENET D, Rediti M, Maetens M, Fumagalli D, et al
     Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.
     Clin Cancer Res. 2021;27:5607-5618.
     PubMed     Abstract available
     
     
     
154. ELKHOLI IE, Foulkes WD, Rivera B
     MRN Complex and Cancer Risk: Old Bottles, New Wine.
     Clin Cancer Res. 2021;27:5465-5471.
     PubMed     Abstract available
     
     
     
155. DOWSETT M, Kilburn L, Rimawi MF, Osborne CK, et al
     Biomarkers of response and resistance to palbociclib plus letrozole in patients with ER+/HER2- breast cancer.
     Clin Cancer Res. 2021 Oct 13. pii: 1078-0432.CCR-21-1628.
     PubMed     Abstract available
     
     
     
156. ASLEH K, Tu D, Gao D, Bramwell V, et al
     Predictive significance of an optimized panel for basal-like breast cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 phase III clinical trials.
     Clin Cancer Res. 2021 Oct 6. pii: 1078-0432.CCR-21-1942.
     PubMed     Abstract available
     
     
     
157. KUEMMEL S, Campone M, Loirat D, Lopez Lopez R, et al
     A Randomized Phase II Study of Anti-CSF-1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple Negative Breast Cancer.
     Clin Cancer Res. 2021 Oct 6. pii: 1078-0432.CCR-20-3955.
     PubMed     Abstract available
     
     
     
158. THORAT MA, Levey PM, Jones JL, Pinder SE, et al
     Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial.
     Clin Cancer Res. 2021;27:5317-5324.
     PubMed     Abstract available
     
     
     September 2021
159. SANCHEZ-GUIXE M, Hierro C, Jimenez J, Viaplana C, et al
     High FGFR1-4 mRNA expression levels correlate with response to selective FGFR inhibitors in breast cancer.
     Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-1810.
     PubMed     Abstract available
     
     
     
160. SCHOUTEN PC, Richters LK, Vis DJ, Kommoss S, et al
     Ovarian cancer specific BRCA-like copy number aberration classifiers detect mutations associated with homologous recombination deficiency in the AGO-TR1 trial.
     Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-1673.
     PubMed     Abstract available
     
     
     
161. PUHALLA SL, Dieras V, Arun BK, Kaufman B, et al
     Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover).
     Clin Cancer Res. 2021;27:4983-4993.
     PubMed     Abstract available
     
     
     
162. WESTIN SN, Labrie M, Litton JK, Blucher A, et al
     Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer.
     Clin Cancer Res. 2021 Sep 13. pii: 1078-0432.CCR-21-1656.
     PubMed     Abstract available
     
     
     August 2021
163. MAITLAND ML, Sachdev JC, Sharma MR, Moreno V, et al
     First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
     Clin Cancer Res. 2021;27:4511-4520.
     PubMed     Abstract available
     
     
     July 2021
164. BLEACH R, Madden SF, Hawley J, Charmsaz S, et al
     Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy.
     Clin Cancer Res. 2021;27:3980-3989.
     PubMed     Abstract available
     
     
     
165. DECENSI A, Puntoni M, Johansson H, Guerrieri-Gonzaga A, et al
     Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease.
     Clin Cancer Res. 2021;27:3576-3583.
     PubMed     Abstract available
     
     
     June 2021
166. STRELL C, Folkvaljon D, Holmberg E, Schiza A, et al
     High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial.
     Clin Cancer Res. 2021;27:3469-3477.
     PubMed     Abstract available
     
     
     
167. COMPTE M, Harwood SL, Erce-Llamazares A, Tapia-Galisteo A, et al
     An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity.
     Clin Cancer Res. 2021;27:3167-3177.
     PubMed     Abstract available
     
     
     May 2021
168. THORAT MA, Levey PM, Jones JL, Pinder SE, et al
     Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ: Results from the UK/ANZ DCIS Trial.
     Clin Cancer Res. 2021;27:2861-2867.
     PubMed     Abstract available
     
     
     
169. TELLI ML, Nagata H, Wapnir I, Acharya CR, et al
     Intratumoral Plasmid IL12 Expands CD8(+) T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy.
     Clin Cancer Res. 2021;27:2481-2493.
     PubMed     Abstract available
     
     
     April 2021
170. HONG DS, Moore KN, Bendell JC, Karp DD, et al
     Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor.
     Clin Cancer Res. 2021;27:1864-1874.
     PubMed     Abstract available
     
     
     
171. CLAUSER P, Krug B, Bickel H, Dietzel M, et al
     Diffusion-weighted Imaging Allows for Downgrading MR BI-RADS 4 Lesions in Contrast-enhanced MRI of the Breast to Avoid Unnecessary Biopsy.
     Clin Cancer Res. 2021;27:1941-1948.
     PubMed     Abstract available
     
     
     March 2021
172. ZHAO M, Scott S, Evans KW, Yuca E, et al
     Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.
     Clin Cancer Res. 2021;27:1681-1694.
     PubMed     Abstract available
     
     
     February 2021
173. LIU CC, Veeraraghavan J, Tan Y, Kim JA, et al
     A Novel Neoplastic Fusion Transcript, RAD51AP1-DYRK4, Confers Sensitivity to the MEK Inhibitor Trametinib in Aggressive Breast Cancers.
     Clin Cancer Res. 2021;27:785-798.
     PubMed     Abstract available
     
     
     October 2020
174. WAHDAN-ALASWAD RS, Edgerton SM, Salem H, Kim H, et al
     Exogenous Thyroid Hormone is Associated with Shortened Survival and Upregulation of High Risk Gene Expression Profiles in Steroid Receptor Positive Breast Cancers.
     Clin Cancer Res. 2020 Oct 23. pii: 1078-0432.CCR-20-2647.
     PubMed     Abstract available
     
     
     August 2020
175. AUTIO KA, Klebanoff CA, Schaer DA, Kauh JS, et al
     Immunomodulatory Activity of a Colony-Stimulating Factor-1 Receptor Inhibitor in Patients With Advanced Refractory Breast or Prostate Cancer: A Phase 1 Study.
     Clin Cancer Res. 2020 Aug 26. pii: 1078-0432.CCR-20-0855.
     PubMed     Abstract available
     
     
     July 2020
176. TOLANEY SM, Sahebjam S, Le Rhun E, Bachelot T, et al
     A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer.
     Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-1764.
     PubMed     Abstract available
     
     
     January 2020
177. KUMTHEKAR P, Tang SC, Brenner AJ, Kesari S, et al
     ANG1005, a brain penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases.
     Clin Cancer Res. 2020 Jan 22. pii: 1078-0432.CCR-19-3258.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.